Shares of Exact Sciences (NASDAQ: EXAS) surged 6.38% in after-hours trading on Monday following the release of its third-quarter 2025 financial results that significantly exceeded analyst expectations.

The molecular diagnostics company reported adjusted earnings per share of $0.28, dramatically beating the consensus estimate of a $0.07 loss. Revenue for the quarter came in at $851 million, surpassing the analyst forecast of $810.1 million and representing a 20% increase from the same period last year.

Exact Sciences' strong performance was driven by robust growth across its key segments. Screening sales, which include its flagship Cologuard colorectal cancer test, reached $2.5 billion, up 20% year-over-year. The precision oncology segment also showed impressive growth, with sales climbing 9% to $710 million.

Kevin Conroy, Chairman and CEO of Exact Sciences, commented on the results: "Our third quarter performance demonstrates the continued strength of our Cologuard and Oncotype DX brands, as well as the exciting potential of our new Cancerguard test in development. We're well-positioned to continue our growth trajectory and make a significant impact in the early detection and treatment of cancer."

The company's adjusted EBITDA for the quarter was $470 million, representing a substantial 47% increase compared to the previous year. This strong profitability improvement, coupled with the revenue beat, likely contributed to the positive after-hours stock reaction.

Investors will be watching closely to see if Exact Sciences can maintain this momentum in the coming quarters, particularly as it continues to invest in new product development and market expansion.